share_log

Johnson & Johnson | 8-K/A: Johnson & Johnson Reports Q1 2024 Results (Amendment)

SEC announcement ·  Apr 17 00:20
Summary by Futu AI
Johnson & Johnson, a leading healthcare company, filed an amended Form 8-K/A with the SEC to correct a typographical error in their initial April 16, 2024, report. The correction adjusts the full-year April 2024 guidance for operational sales from $88.0 billion to $88.9 billion. The company announced its Q1 2024 results, reporting a 2.3% increase in sales to $21.4 billion, with operational growth of 3.9% and adjusted operational growth of 4.0%. Excluding the COVID-19 vaccine, adjusted operational growth was 7.7%. First-quarter EPS rose to $2.20, with adjusted EPS increasing by 12.4% to $2.71. Johnson & Johnson also raised its full-year 2024 operational sales and adjusted operational EPS guidance. The company's performance was driven by strong sales in its Innovative Medicine and MedTech segments, with notable growth in oncology, pulmonary hypertension, immunology, and neuroscience products. Additionally, the company highlighted several regulatory approvals, product launches, and acquisitions, emphasizing its commitment to innovation and leadership in healthcare.
Johnson & Johnson, a leading healthcare company, filed an amended Form 8-K/A with the SEC to correct a typographical error in their initial April 16, 2024, report. The correction adjusts the full-year April 2024 guidance for operational sales from $88.0 billion to $88.9 billion. The company announced its Q1 2024 results, reporting a 2.3% increase in sales to $21.4 billion, with operational growth of 3.9% and adjusted operational growth of 4.0%. Excluding the COVID-19 vaccine, adjusted operational growth was 7.7%. First-quarter EPS rose to $2.20, with adjusted EPS increasing by 12.4% to $2.71. Johnson & Johnson also raised its full-year 2024 operational sales and adjusted operational EPS guidance. The company's performance was driven by strong sales in its Innovative Medicine and MedTech segments, with notable growth in oncology, pulmonary hypertension, immunology, and neuroscience products. Additionally, the company highlighted several regulatory approvals, product launches, and acquisitions, emphasizing its commitment to innovation and leadership in healthcare.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.